BACKGROUND: Statins are known to possess pleiotropic anti-inflammatory properties which have been evaluated for clinical benefits in a number of disorders. Studies have demonstrated beneficial actions of statins in experimental models of colitis. Clinical evidence in acute exacerbation of ulcerative colitis (UC) is lacking. AIM: This study aims to assess the efficacy and safety of add-on atorvastatin in mild to moderately severe acute exacerbation of UC. METHODS:Patients with acute exacerbation of UC were randomized to receive either atorvastatin (20 mg) or matching placebo once daily orally for 8 weeks in addition to the standard therapy. Clinical efficacy was assessed by using partial Mayo score (PMS). RESULTS:Previously diagnosed 64 cases of UC presenting with mild to moderately severe acute exacerbation were randomized to receive either atorvastatin of 20 mg or placebo. Mean PMS increased by 1.5 points and decreased by 0.31 points in atorvastatin and placebo groups, respectively, at 8 weeks compared to the baseline values (p = 0.04). Eight (25 %) and 13 (40.6 %) patients attained the primary outcome criteria for clinical improvement in the atorvastatin and placebo arms, respectively (p = 0.18). Fifteen (46.8 %) patients in the atorvastatin group and no patient in the placebo group had ≥2 point increase in PMS after 8 weeks (p < 0.001). CONCLUSION:Atorvastatin therapy in acute exacerbation of UC may not be associated with beneficial effects. Paradoxical increase in disease activity may be seen in some patients. However, these findings need to be substantiated in larger studies.
RCT Entities:
BACKGROUND: Statins are known to possess pleiotropic anti-inflammatory properties which have been evaluated for clinical benefits in a number of disorders. Studies have demonstrated beneficial actions of statins in experimental models of colitis. Clinical evidence in acute exacerbation of ulcerative colitis (UC) is lacking. AIM: This study aims to assess the efficacy and safety of add-on atorvastatin in mild to moderately severe acute exacerbation of UC. METHODS:Patients with acute exacerbation of UC were randomized to receive either atorvastatin (20 mg) or matching placebo once daily orally for 8 weeks in addition to the standard therapy. Clinical efficacy was assessed by using partial Mayo score (PMS). RESULTS: Previously diagnosed 64 cases of UC presenting with mild to moderately severe acute exacerbation were randomized to receive either atorvastatin of 20 mg or placebo. Mean PMS increased by 1.5 points and decreased by 0.31 points in atorvastatin and placebo groups, respectively, at 8 weeks compared to the baseline values (p = 0.04). Eight (25 %) and 13 (40.6 %) patients attained the primary outcome criteria for clinical improvement in the atorvastatin and placebo arms, respectively (p = 0.18). Fifteen (46.8 %) patients in the atorvastatin group and no patient in the placebo group had ≥2 point increase in PMS after 8 weeks (p < 0.001). CONCLUSION:Atorvastatin therapy in acute exacerbation of UC may not be associated with beneficial effects. Paradoxical increase in disease activity may be seen in some patients. However, these findings need to be substantiated in larger studies.
Authors: Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil Journal: Nature Date: 2002-11-07 Impact factor: 49.962
Authors: Seth D Crockett; Richard A Hansen; Til Stürmer; Robin Schectman; Jane Darter; Robert S Sandler; Michael D Kappelman Journal: Inflamm Bowel Dis Date: 2011-08-08 Impact factor: 5.325
Authors: James D Lewis; Shaokun Chuai; Lisa Nessel; Gary R Lichtenstein; Faten N Aberra; Jonas H Ellenberg Journal: Inflamm Bowel Dis Date: 2008-12 Impact factor: 5.325
Authors: David W McCarey; Iain B McInnes; Rajan Madhok; Rosie Hampson; Olga Scherbakov; Ian Ford; Hilary A Capell; Naveed Sattar Journal: Lancet Date: 2004-06-19 Impact factor: 79.321
Authors: Lawrence Bai; Madeleine K D Scott; Ethan Steinberg; Laurynas Kalesinskas; Aida Habtezion; Nigam H Shah; Purvesh Khatri Journal: J Am Med Inform Assoc Date: 2021-10-12 Impact factor: 4.497
Authors: Bruce E Sands; Jean-Frédéric Colombel; Christina Ha; Michel Farnier; Alessandro Armuzzi; Daniel Quirk; Gary S Friedman; Kenneth Kwok; Leonardo Salese; Chinyu Su; Pam R Taub Journal: Inflamm Bowel Dis Date: 2021-05-17 Impact factor: 5.325